These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17438478)

  • 1. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors.
    Kiguba R; Byakika-Tusiime J; Karamagi C; Ssali F; Mugyenyi P; Katabira E
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):218-23. PubMed ID: 17438478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
    Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
    HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
    Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD;
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):743-52. PubMed ID: 16218797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
    d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
    AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda.
    Kyeyune R; Saathoff E; Ezeamama AE; Löscher T; Fawzi W; Guwatudde D
    BMC Infect Dis; 2014 Sep; 14():496. PubMed ID: 25209550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda.
    Weidle PJ; Moore D; Mermin J; Buchacz K; Were W; Downing R; Kigozi A; Ndazima V; Peters P; Brooks JT
    AIDS Patient Care STDS; 2008 Oct; 22(10):787-95. PubMed ID: 18778241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.
    Sow PS; Otieno LF; Bissagnene E; Kityo C; Bennink R; Clevenbergh P; Wit FW; Waalberg E; Rinke de Wit TF; Lange JM;
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):262-7. PubMed ID: 17146376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 2007 to May 2009.
    Namukwaya Z; Mudiope P; Kekitiinwa A; Musoke P; Matovu J; Kayma S; Salmond W; Bitarakwate E; Mubiru M; Maganda A; Galla M; Byamugisha J; Fowler MG
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):69-75. PubMed ID: 21099692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to initial highly active antiretroviral therapy discontinuation and its predictors among HIV patients in Felege Hiwot comprehensive specialized hospital: a retrospective cohort study.
    Amera TG; Bogale KA; Tefera YM
    AIDS Res Ther; 2021 Dec; 18(1):93. PubMed ID: 34863200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden.
    Hill S; Kavookjian J; Qian J; Chung A; Vandewaa J
    AIDS Care; 2014; 26(5):595-601. PubMed ID: 24111921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
    Kumarasamy N; Vallabhaneni S; Cecelia AJ; Yepthomi T; Balakrishnan P; Saghayam S; Flanigan TP; Carpenter CC; Solomon S; Mayer KH
    J Acquir Immune Defic Syndr; 2006 Jan; 41(1):53-8. PubMed ID: 16340473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
    AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in rural Uganda.
    Homsy J; Moore D; Barasa A; Were W; Likicho C; Waiswa B; Downing R; Malamba S; Tappero J; Mermin J
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):28-35. PubMed ID: 19797972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
    Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD;
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):527-36. PubMed ID: 15989457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.
    Mocroft A; Youle M; Moore A; Sabin CA; Madge S; Lepri AC; Tyrer M; Chaloner C; Wilson D; Loveday C; Johnson MA; Phillips AN
    AIDS; 2001 Jan; 15(2):185-94. PubMed ID: 11216926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.